Welcome to our dedicated page for Catheter Precision SEC filings (Ticker: VTAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the FDA trial outcomes buried in Catheter Precision’s 10-K can feel like navigating a cardiac maze. The disclosures span VIVO non-invasive mapping performance, LockeT vascular-closure margins, and CE-mark timelines—details investors need but rarely have time to parse. It’s why so many search “Catheter Precision SEC filings explained simply” or ask for a “Catheter Precision annual report 10-K simplified.”
Stock Titan decodes the complexity the instant an update hits EDGAR. Whether you’re looking for a “Catheter Precision quarterly earnings report 10-Q filing” or want “Catheter Precision 8-K material events explained,” our AI delivers crisp summaries, red-flag callouts, and trend charts. Real-time alerts push “Catheter Precision Form 4 insider transactions real-time” straight to your dashboard, so you know the moment executives trade shares. For professionals, understanding Catheter Precision SEC documents with AI is now as direct as a chart review.
Use the filings the way seasoned analysts do:
- Product economics: 10-Q segments reveal average selling prices for VIVO; our AI spots sequential changes.
- Regulatory momentum: Each 8-K logs new clinical milestones, instantly summarized for quick context.
- Capital needs: Shelf registrations hint at funding rounds for additional catheter studies.
If governance is your focus, one click surfaces the “Catheter Precision proxy statement executive compensation” tables alongside peer benchmarks. Need “Catheter Precision insider trading Form 4 transactions” or “Catheter Precision executive stock transactions Form 4”? Our AI clusters every buy and sell by date, value, and intent. The result: concise “Catheter Precision earnings report filing analysis” in seconds—not evenings—turning dense disclosures into confident, timely decisions.
Catheter Precision, Inc. (VTAK) filed a Form S-8 on 26 June 2025 to register shares issuable under two employee equity programs: (1) the Catheter Precision 2023 Equity Incentive Plan and (2) a stand-alone stock-option grant dated 6 Jan 2025 to CFO Philip Anderson. The filing allows the Company to issue these shares to employees without additional SEC registration, thereby facilitating equity-based compensation.
Registrant profile: Delaware corporation, non-accelerated filer, smaller reporting company, principal offices in Fort Mill, SC. The registration statement incorporates by reference the Company’s 2024 Form 10-K (filed 31 Mar 2025, amended 30 Apr 2025), Q1-2025 Form 10-Q (filed 14 May 2025) and thirteen Form 8-Ks filed between 7 Jan and 13 Jun 2025. These filings collectively provide investors the requisite financial and operational background.
Legal & governance highlights: The document reiterates broad indemnification protections for directors and officers under Delaware law and the Company’s bylaws, including advancement of expenses. The SEC’s longstanding position that indemnification for Securities Act liabilities is unenforceable is also acknowledged.
Exhibits of note: (i) legal opinion on share legality (Ex. 5.1), (ii) auditor consent (Ex. 23.2), (iii) full 2023 Incentive Plan (Ex. 99.1) and the individual non-plan option award (Ex. 99.2). Exhibit 107 contains the fee table; specific share counts and aggregate offering value are not provided in the excerpt.
Investor impact: Because S-8 registrations are routine administrative matters with no immediate cash proceeds, the filing is operationally neutral. Over time, however, issuances under the plan will increase the fully diluted share count and may introduce incremental dilution.
FAQ
What is the current stock price of Catheter Precision (VTAK)?
What is the market cap of Catheter Precision (VTAK)?
What is Catheter Precision's primary focus?
What are the flagship products offered by the company?
How does the VIVO System enhance electrophysiology procedures?
What makes the LockeT device significant in vascular closure?
How does Catheter Precision ensure the quality of its products?
What role do strategic partnerships play for Catheter Precision?
How does Catheter Precision differentiate itself from competitors?
What drives the ongoing innovation at Catheter Precision?
